Dyadic International, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark A. Emalfarb
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 140 Intracoastal Pointe Drive Jupiter FL United States of America 33477-5094
- IPO Date
- Jan 16, 2008
- CIK
- 0001213809
- Website
- dyadic.com
- Similar Companies
- Business
- Dyadic International, Inc. Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company that develops and commercializes proprietary microbial expression platforms, including the C1 and Dapibus expression systems based on the fungal host Thermothelomyces heterothallica, for the scalable production of high-value recombinant proteins and enzymes; these platforms enable the manufacture of animal-free input proteins for life sciences applications such as research reagents, diagnostics, therapeutics, bioprocess inputs including recombinant human albumin and transferrin, food and nutrition ingredients like non-animal dairy enzymes, and bio-industrial enzymes for biofuels, textiles, specialty chemicals, and cellulosic biomass conversion via products such as the EN3ZYME cocktail. Founded in 1979 and headquartered in Jupiter, Florida, the company originally focused on industrial enzymes and textiles before transitioning to biotechnology, serving customers across life sciences, food and nutrition, and bio-industrial markets worldwide with GRAS-designated, cGMP-capable production validated at scales exceeding 100,000 liters. In 2025, Dyadic Applied BioSolutions rebranded to emphasize applied biotechnology solutions, completed a strategic pivot from R&D to commercial revenue focus with first bulk protein sales, achieved multiple milestones including $1.5 million in payments from its Proliant Health & Biologicals partnership for recombinant human albumin targeting commercial launch in late 2025 or early 2026, advanced collaborations with Inzymes ApS and Fermbox Bio yielding purchase orders and 50/50 profit sharing on EN3ZYME, entered a non-exclusive CRISPR/Cas9 license with ERS Genomics to enhance genetic engineering capabilities, expanded into Japan and South Korea via partnership with Intralink, and conducted a public stock offering to fund product development and marketing.
Dyadic Expands IP Protection and Business Development Activities in Japan
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
Dyadic International (NASDAQ:DYAI) Share Price Crosses Below 50 Day Moving Average – Should You Sell?
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets